Grifols
Also known as: Albimmune SL | Biomat USA, Inc | Biomat USA, Inc. | Biomat USA, Inc. (Sponsor) | Grifols Biologicals Inc. | Grifols Biologicals LLC | Grifols Biologicals, LLC | Grifols Diagnostics Solutions, Inc | Grifols Japan K.K. | Grifols Shared Services North America | Grifols Therapeutics | Grifols Therapeutics Inc. | Grifols Therapeutics LLC | Grifols Therapeutics, LLC | Instituto Grifols, S.A. | LABORATORIOS GRIFOLS | omitja@flsida.org, +3493 4978339
Highest phase reached
Phase 4
First clinical trial
Nov 1, 1999First marketed drug
Oct 21, 1942First NDA
Oct 21, 1942Last known activity
Dec 16, 2025
Timeline
1940s
- Jan 1, 1940
Grifols— Founded
1970s
- Jun 11, 1971
Rho(D) Immune Globulin Intravenous (Human)— NDA Secondary Org
- Jun 11, 1971
Rho(D) Immune Globulin Intravenous (Human)— NDA Organization
2000s
- Jan 1, 2003
Alpha Therapeutic Corporation— Acquired
2010s
- Jan 1, 2010
Talecris Biotherapeutics— Acquired
- Mar 19, 2012
Araclon Biotech S.L.— Acquired
- May 25, 2017
sodium chloride— Marketing Organization
2020s
- Sep 9, 2020
Alkahest, Inc.— Acquired
- Mar 9, 2021
GigaGen— Acquired
- Sep 17, 2021
Biotest Pharmaceuticals— Acquired
Drugs by trial phase (47 distinct, 146 trials)
Phase 4 (5 own, 4 via acquisition)
Phase 3 (10 own, 5 via acquisition)
- human fibrin
- alpha-1 antitrypsin
- naltrexone
- fibrinogen (human)
- ciprofloxacin
- hepatitis b immune globulin (human)
- antithrombin iii (human)
- blood plasma
- thrombin (human coagulation factor iia)
- sodium chloride
- glucose monohydrate
- thrombin (human coagulation factor iia) (Recombinant)
- IgM Concentrate
- covid 19 immune globulin
- bt097
Phase 2 (6 own, 12 via acquisition)
Phase 1 (1 own, 3 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Acute Kidney Injury
- Acute-On-Chronic Liver Failure
- Afibrinogenemia
- Agammaglobulinemia
- alpha 1-Antitrypsin Deficiency
- Alzheimer Disease
- Amyloidosis
- Amyotrophic Lateral Sclerosis
- Antithrombin III Deficiency
- Arterial Occlusive Diseases
- Ascites
- Brain Diseases
- Bronchiectasis
- Common Variable Immunodeficiency
- Communicable Diseases
- Coronavirus Infections
- Crohn Disease
- Cystic Fibrosis
- Deficiency Diseases
- Diabetes Complications
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetic Neuropathies
- Diphtheria
- Emphysema
- End Stage Liver Disease
- Epilepsy
- Fibrosis
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Hepatic Encephalopathy
- Hepatic Insufficiency
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis B, Chronic
- HIV Infections
- Hypotension
- IgG Deficiency
- Immunologic Deficiency Syndromes
- Infections
- Ischemia
- Liver Cirrhosis
- Liver Failure
- Lung Diseases, Obstructive
- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic
- Macular Degeneration
- Motor Neuron Disease
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Muscle Weakness
- Muscular Diseases
- Myasthenia Gravis
- Peripheral Nervous System Diseases
- Poliomyelitis
- Polyneuropathies
- Polyradiculoneuropathy
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Postpoliomyelitis Syndrome
- Postural Orthostatic Tachycardia Syndrome
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Emphysema
- Purpura
- Purpura, Thrombocytopenic
- Purpura, Thrombocytopenic, Idiopathic
- Rabies
- Recurrence
- Sclerosis
- Severe Combined Immunodeficiency
- Shock
- Shock, Septic
- Stiff-Person Syndrome
- Stroke
- Syndrome
- Tachycardia
- Tetanus
- Tetany
- Thrombosis
- Venous Thrombosis
- von Willebrand Diseases
- Wiskott-Aldrich Syndrome
Marketed drugs (16)
- thrombin (bovine)
- alpha-1 antitrypsin
- albumin (Human)
- fibrinogen (human)
- human factor ix complex (prothrombin complex concentrate)
- immune globulin (human)
- rabies immune globulin (human)
- tetanus immunoglobulin
- von Willebrand factor
- hepatitis b immune globulin (human)
- antithrombin iii (human)
- Rho(D) Immune Globulin Intravenous (Human)
- sodium chloride
- human coagulation factor ix
- antihemophilic factor viii human
- Plasma Protein Fraction (Human)
Subsidiaries (6 direct, 6 total across the full acquisition tree)
Recent trials (50)
- NCT07264517Lead sponsorPhase 2Nov 3, 2025
- NCT06052176CollaboratorPhase 2Oct 1, 2023
- NCT05645887Lead sponsorPhase 2Jan 31, 2023
- NCT05645107Lead sponsorPhase 3Dec 17, 2022
- NCT05357339CollaboratorN/ASep 1, 2021
- NCT04722887Lead sponsorPhase 1/Phase 2Aug 13, 2021
- NCT04899232CollaboratorPhase 2Jul 6, 2021
- NCT04847141Lead sponsorPhase 3Apr 28, 2021
- NCT04847141Overall official - principal investigatorPhase 3Apr 28, 2021
- NCT04547140Lead sponsorPhase 2Dec 31, 2020
- NCT04566692Lead sponsorPhase 4Dec 19, 2020
- NCT04636268Lead sponsorPhase 3Nov 30, 2020
- NCT04450654CollaboratorPhase 2Nov 1, 2020
- NCT04621123CollaboratorPhase 2Oct 30, 2020
- NCT04561115Lead sponsorPhase 3Oct 6, 2020
Details
- Founded
- Barcelona, ES Jan 1, 1940
- First NDA
- Oct 21, 1942
- Last known activity
- Dec 16, 2025
Designations held
- Orphan drug